CD38 and acute myeloid leukemia: Moreover, compared with anti-CD47 (5F9) and daratumumab, ISB 1442 also mediates increased phagocytosis of T-ALL and AML tumor cells in cell lines with reduced CD38 and CD47 expression (23).